Zusammenfassung
Die Nutzung der Hanfpflanze (Cannabis L.) und ihrer Produkte durch den Menschen zu religiösen und medizinischen Zwecken, aber auch wegen ihrer euphorischen und entspannenden Wirkung, reicht tausende von Jahren zurück. Der Hanf gehört ebenso wie die Gattung Humulus (Hopfen) der Familie der Cannabaceae (Hanfgewächse) an. Die Anzahl der Arten in der Gattung Cannabis wurde lange diskutiert und bleibt weiterhin umstritten. Gegenstand der Debatte war die Frage, ob Cannabis sativa, Cannabis indica und Cannabis ruderalis jeweils eigene Arten darstellen. Aktuell wird meist eine einzige vielfältige Art (Cannabis sativa L.) mit verschiedenen Variationen angenommen, andere Forscher plädieren dagegen für eine Unterteilung in zwei getrennte Arten (Cannabis sativa und Cannabis indica).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Alger BE (2012) Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know. J Physiol 590 (10): 2203–2212
Ameri A (1999) The effects of cannabinoids on the brain. Progress in neurobiology 58 (4): 315–348
Argue KJ, VanRyzin JW, Falvo DJ, Whitaker AR, Yu SJ, McCarthy MM (2017) Activation of Both CB1 and CB2 Endocannabinoid Receptors is critical for masculinization of the developing medial Amygdala and Juvenile Social Play Behavior. eNeuro 4 (1): 0344–0316.2017. doi: 10.1523/ENEURO.0344-16.2017.
Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160 (3): 467–479
Baik J-H (2013) Dopamine signaling in reward-related behaviors. Frontiers in neural circuits 7
Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995) The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17 (1): 25–30
Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T (2007) Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316 (5828): 1212–1216
Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernández-Ruiz JJ (1999) Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33 (3): 181–191
Blankman JL, Cravatt BF (2013) Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65 (2): 849–871
Brents LK (2016) Marijuana, the Endocannabinoid System and the Female Reproductive System. Yale J Biol Med 89 (2): 175–191
Brown A (2007) Novel cannabinoid receptors. Br J Pharmacol 152 (5): 567–575
Buczynski MW, Parsons LH (2010) Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol 160 (3): 423–442
Busquets-Garcia A, Bains J, Marsicano G (2017) CB1 Receptors signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology. doi: 10.1038/npp.2017.206
Cahill L (2006) Why sex matters for neuroscience. Nature Rev Neurosci 7 (6): 477
Cascini F, Aiello C, Di Tanna G (2012) Inreasing delta-9-tetrahydrocannabinol content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5 (1): 32–40
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144: 12–41. doi: 10.1016/j.drugalcdep.2014.08.005
Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76 (1): 70–81. doi: 10.1016/j.neuron.2012.09.020
Choi K, Le T, McGuire J, Xing G, Zhang L, Li H, Parker CC, Johnson LR, Ursano RJ (2012) Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res 46 (7): 882–889. doi: 10.1016/j.jpsychires.2012.03.021
Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci 92 (8–9): 476–481. doi: 10.1016/j.lfs.2012.06.009
de Fonseca FR, Ramos JA, Bonnin A, Fernández-Ruiz JJ (1993) Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4 (2): 135–138
Devane WA, Dysarz Fr, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (5): 605–613
Diaz-Alonso J, Aguado T, Wu C-S, Palazuelos J, Hofmann C, Garcez P, Guillemot F, Lu H-C, Lutz B, Guzman M, Galve-Roperh I (2012) The CB (1) cannabinoid receptor drives corticospinal motor neuron differentiation through the Ctip2/Satb2 transcriptional regulation axis. J Neurosci 32 (47): 16651–16665. doi: 10.1523/JNEUROSCI.0681-12.2012
Diaz S, Farhang B, Hoien J, Stahlman M, Adatia N, Cox JM, Wagner EJ (2009) Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses. Neuroendocrinology 89 (4): 424–440
Du Plessis SS, Agarwal A, Halabi J, Tvrda E (2015) Contemporary evidence on the physiological role of reactive oxygen species in human sperm function. J Assist Reprod Genet 32 (4): 509–520
Dujourdy L, Besacier F (2017) A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sci Int 272: 72–80. doi: 10.1016/j.forsciint.2017.01.007
Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142 (3): 295–301
El Khoury M-A, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET (2012) Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Prog Neuro-Psychopharmacol Biol Psychiat 38 (1): 36–50
Elphick MR (2012) The evolution and comparative neurobiology of endocannabinoid signalling. Philos Trans R Soc London Ser B Biol Sci 367 (1607): 3201–3215. doi: 10.1098/rstb.2011.0394
ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiat 79 (7): 613–619. doi: 10.1016/j.biopsych.2016.01.004
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A (2017) Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 103: 1–36. doi: 10.1007/978-3-319-45541-9_1
Esteban S, García-Sevilla JA (2012) Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiat 38 (1): 78–87
Fattore L, Fratta W (2010) How important are sex differences in cannabinoid action? Br J Pharmacol 160 (3): 544–548
Fernández-Ruiz J, Berrendero F, Hernandez M, Romero J, Ramos J (1999) Role of endocannabinoids in brain development. Life Sci 65 (6): 725–736
Fernández-Ruiz J, Berrendero F, Hernández ML, Ramos JA (2000) The endogenous cannabinoid system and brain development. Trends Neurosci 23 (1): 14–20
Friedman D, Sirven J (2017) Historical perspective on the medial use of cannabis for epilepsy: Ancient times to the 1980s. Epilepsy Behav 70 (Pt B): 298–301. doi: 10.1016/j.yebeh.2016.11.033
Fügedi G, Molnár M, Rigó J, Schönléber J, Kovalszky I, Molvarec A (2014) Increased placental expression of cannabinoid receptor 1 in preeclampsia: an observational study. BMC pregnancy and childbirth 14 (1): 395
Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. The FEBS J 232 (1): 54–61
Garcia AB, Soria-Gomez E, Bellocchio L, Marsicano G (2016a) Cannabinoid receptor type-1: breaking the dogmas. F1000Research 5
Garcia C, Palomo-Garo C, Gomez-Galvez Y, Fernandez-Ruiz J (2016b) Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol 173 (13): 2069–2079. doi: 10.1111/bph.13215
Garcia MC, Cinquina V, Palomo-Garo C, Rabano A, Fernandez-Ruiz J (2015) Identification of CB (2) receptors in human nigral neurons that degenerate in Parkinson’s disease. Neurosci Lett 587: 1–4. doi: 10.1016/j.neulet.2014.12.003
Gertsch J, Pertwee RG, Di Marzo V (2010) Phytocannabinoids beyond the Cannabis plant – do they exist? Br J Pharmacol 160 (3): 523–529. doi: 10.1111/j.1476-5381.2010.00745.x
Giedd JN, Raznahan A, Mills KL, Lenroot RK (2012) magnetic resonance imaging of male/female differences in human adolescent brain anatomy. Biology of Sex Differences 3 (1): 19
Giuffrida A, Parsons L, Kerr T, deFonseca FR, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature neuroscience 2 (4)
Hermann D, Schneider M (2012) Potential protective effects of cannabidiol onneuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharmaceut Design 18 (32): 4897–4905
Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss U (2015) Risks associated with the non-medicinal use of cannabis. Dtsch Aerzteblatt Int 112 (16): 271–278. doi: 10.3238/arztebl.2015.0271
Hu SS-J, Mackie K (2015) Distribution of the endocannabinoid system in the central nervous system. In: Endocannabinoids. Springer, pp 59–93
James A, James C, Thwaites T (2013) The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiat Res 214 (3): 181–189. doi: 10.1016/j.pscychresns.2013.07.012
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89 (1): 309–380. doi: 10.1152/physrev.00019.2008
Katona I, Freund T (2012) Multiple funktions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35: 529–558. doi: 10.1146/annurev-neuro-062111-150420
Kendall DA, Yudowski GA (2016) Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Frontiers in cellular neuroscience 10
Klugmann M, Klippenstein V, Leweke FM, Spanagel R, Schneider M (2011) Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels. International J Neuropsychopharmacology 14 (4): 505–517
Krebs-Kraft DL, Hill MN, Hillard CJ, McCarthy MM (2010) Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior. Proceedings of the National Academy of Sciences 107 (47): 20535–20540
Laursen L (2015) Botany: The cultivation of weed. Nature neuroscience 525 (7570): S4–5. doi: 10.1038/525S4a
Ligresti A, Villano R, Allara M, Ujvary I, Di Marzo V (2012) Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB (1) receptor ligand. Pharmacol Res 66 (2): 163–169. doi: 10.1016/j.phrs.2012.04.003
Long LE, Lind J, Webster M, Weickert CS (2012) Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neuroscience 13: 87–87. doi: 10.1186/1471-2202-13-87
López HH (2010) Cannabinoid-hormone interactions in the regulation of motivational processes. Hormones and behavior 58 (1): 100–110
Lu H-C, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiat 79 (7): 516–525
Lutz B, Marsicano G, Maldonado R, Hillard CJ (2015) The endocannabinoid system in guarding against fear, anxiety and stress. Nature Rev Neurosci 16 (12): 705–718. doi: 10.1038/nrn4036
Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36 (5): 277–296. doi: 10.1016/j.tips.2015.02.008
Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T (2014) Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. 2014 15 (12): 786–801. doi: 10.1038/nrn3846
Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Cannabinoids: 299–325
Malfitano AM, Basu S, Maresz K, Bifulco M, Dittel BN What we know and do not know about the cannabinoid receptor 2 (CB2). In: Seminars in immunology, 2014. vol 5. Elsevier, pp 369–379
Mato S, Del Olmo E, Pazos A (2003) Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. European J Neuroscience 17 (9): 1747–1754
Mato S, Pazos A (2004) Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 46 (5): 716–726
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bronner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (6284): 561
McEwen BS, Milner TA (2017) Understanding the broad influence of sex hormones and sex differences in the brain. J neuroscience research 95 (1–2): 24–39
McLaughlin CR, Martin BR, Compton DR, Abood ME (1994) Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. Drug Alcohol Depend 36 (1): 27–31
McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol und Delta (9)-tetrahydrocannabivarin negative modulators or the endocannabinoid system? A systematic review. Br J Pharmacol 172 (3): 737.753. doi: 10.1111/bph.12944
Mechoulam R, Hanus LO, Pertwee R, Howlett AC (2014) Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Rev Neurosci 15 (11): 757–764. doi: 10.1038/nrn3811
Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109 (40): E2657–2664. doi: 10.1073/pnas.1206820109
Melis M, Pistis M (2012) Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Phil Trans R Soc B 367 (1607): 3276–3285
Meyer HC, Lee FS, Gee DG (2017) The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development. Neuropsychopharmacology. doi: 10.1038/npp.2017.143
Monshouwer K, Smit F, de Graaf R, van Os J, Vollebergh W (2005) First cannabis use: does onset shift to younger ages? Findings from 1988 to 2003 from the Dutch National School Survey on Substance Use. Addiction 100 (7): 963–970. doi: 10.1111/j.1360-0443.2005.01088.x
Morales P, Hurst DP, Reggio PH (2017) Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod 103: 103–131. doi: 10.1007/978-3-319-45541-9_4
Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, Monory K, Marsicano G, Di Marzo V, Hurd YL, Guillemot F, Mackie K, Lutz B, Guzman M, Lu H-C, Galve-Roperh I, Harkany T (2008) Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci USA 105 (25): 8760–8765. doi: 10.1073/pnas.0803545105
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (6441): 61–65
Orsolini L, Papanti D, Corkery J, De Luca MA, Cadoni C, Di Chiara G, Schifano F (2017) Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics” („Spice”) intake? CNS Neurol Disord Drug Targets. doi: 10.2174/1871527316666170413101257
Pavlova MA (2016) Sex and gender affect the social brain: beyond simplicity. J neuroscience research
Pertwee R (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367 (1607): 3353–3363. doi: 10.1098/rstb.2011.0381
Pertwee RG (2014) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc 73 (1): 96–105. doi: 10.1017/s0029665113003649
Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nature Rev Neurosci 4 (11): 873
Richardson KA, Hester AK, McLemore GL (2016) Prenatal cannabis exposure-The „first hit” to the endocannabinoid system. Neurotoxicol Teratol 58: 5–14
Russo E (2007) History of cannabis and its preparations in saga, science, and sobriquet. Chemistry & biodiversity 4 (8): 1614–1648
Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13 (2): 253–263. doi: 10.1111/j.1369-1600.2008.00110.x
Schneider M (2009) Cannabis use in pregnancy and early life and its consequences: animal models. Eur Arch Psychiat Clin Neurosci 259 (7): 383–393. doi: 10.1007/s00406-009-0026-0
Schneider M (2013) Adolescence as a vulnerable period to alter rodent behavior. Cell tissue Res 354 (1): 99–106. doi: 10.1007/s00441-013-1581-2
Schneider M, Kasanetz F, Lynch DL, Friemel CM, Lassalle O, Hurst DP, Steindel F, Monory K, Schafer C, Miederer I, Leweke FM, Schreckenberger M, Lutz B, Reggio PH, Manzoni OJ, Spanagel R (2015) Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. J Neurosci 35 (41): 13975–13988. doi: 10.1523/jneurosci.1937-15.2015
Schneider M, Levant B, Reichel M, Gulbins E, Kornhuber J, Muller CP (2017) Lipids in psychiatric disorders and preventive medicine. Neurosci Biobehav Rev 76 (Pt B): 336–362. doi: 10.1016/j.neurobiorev.2016.06.002
Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ (2013) Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Progress in neurobiology 106: 1–16
Sierra S, Luquin N, Rico AJ, Gomez-Bautista V, Roda E, Dopeso-Reyes IG, Vazquez A, Martinez-Pinilla E, Labandeira-Garcia JL, Franco R, Lanciego JL (2015) Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain structure & function 220 (5): 2721–2738. doi: 10.1007/s00429-014-0823-8
Smith TH, Sim-Selley LJ, Selley DE (2010) Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160 (3): 454–466
Solowij N, Battisti R (2008) The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1 (1): 81–98
Sossin WS, DesGroseillers L (2006) Intracellular trafficking of RNA in neurons. Traffic (Copenhagen, Denmark) 7 (12): 1581–1589. doi: 10.1111/j.1600-0854.2006.00500.x
Stempel AV, Stumpf A, Zhang H-Y, Ozdogan T, Pannasch U, Theis A-K, Otte D-M, Wojtalla A, Racz I, Ponomarenko A, Xi Z-X, Zimmer A, Schmitz D (2016) Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus. doi: 10.1016/j.neuron.2016.03.034
Svizenska I, Dubovy P, Sulcova A (2008) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures – a short review. Pharmacol Biochem Behav 90 (4): 501–511. doi: 10.1016/j.pbb.2008.05.010
Swift W, Wong A, Arnold J, MdGregor I (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PloS one 8 (7): e70052. doi: 10.1371/journal.pone.0070052. Print 2013
Tortoriello G, Morris C, Alpar A, Fuzik J, Shirran SL, Calvigiono D, Keimpema E, Botting CH, Reinecke K, Herdegen T, Courtney M, Hurd YL, Harkany T (2014) Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 33 (7): 668–685. doi: 10.1002/embj.201386035
Vallee M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martiin-Garcia E, Kasanetz F, Baillie GL, Panin F, Cathala A, Roullot-Lacarriere V, Fabre S, Hurst DP, Lynch DL, Shore DM, Deroche-Gamonet V, Spampinato U, Revest J-M, Maldonado R, Reggio PH, Ross RA, Marsicano G, Piazza PV (2014) Pregnenolone can protect the brain from cannabis intoxication. Science 343 (6166): 94–98. doi: 10.1126/science.1243975
van Amsterdam J, Brunt T, van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29 (3): 254–263. doi: 10.1177/0269881114565142
van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480 (1): 133–150
Vinals X, Moreno E, Lanfumey L, Cordomi A, Pastor A, de La Torre R, Gasperini P, Navarro G, Howell LA, Pardo L, Lluis C, Canela EI, McCormick PJ, Maldonado R, Robledo P (2015) Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. PLOS Biol 13 (7): e1002194. doi: 10.1371/journal.pbio.1002194.
Wenger T, Croix D, Tramu G (1988) The effect of chronic prepubertal administration of marihuana (delta-9-tetrahydrocannabinol) on the onset of puberty and the postpubertal reproductive functions in female rats. Biology of reproduction 39 (3): 540–545
Wenger T, Gerendai I, Fezza F, González S, Bisogno T, Fernandez-Ruiz J, Di Marzo V (2002) The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sci 70 (12): 1407–1414
Westlake T, Howlett A, Bonner T, Matsuda L, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience 63 (3): 637–652
Wu C-S, Zhu J, Wager-Miller J, Wang S, O’Leary D, Monory K, Lutz B, Mackie K, Lu H-C (2010) Requirement of cannabinoid CB (1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci 32 (5): 693–706. doi: 10.1111/j.1460-9568.2010.07337.x.
Zamengo L, Frison G, Bettin C, Sciarrone R (2015) Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal 7 (3): 255–258. doi: 10.1002/dta.1690
Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, Gardner EL, Wu J, Xi ZX (2014) Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci USA 111 (46): E5007–5015. doi: 10.1073/pnas.1413210111
Zurolo E, Iyer AM, Spliet WG, Van Rijen PC, Troost D, Gorter JA, Aronica E (2010) CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. Neuroscience 170 (1): 28–41. doi: 10.1016/j.neuroscience.2010.07.004
Zygmunt PM, Petersson J, Andersson DA, Chuang H-h, Sørgård M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (6743): 452–457
Baumgärtner T, Kestler J (2014) Suchtmittelgebrauch, Computerspielverhalten, Internetnutzung und Glücksspielerfahrungen von Jugendlichen in Hamburg und5 kommunalen Modellregionen in Deutschland. Deskriptive Ergebnisse der SCHULBUSregional-Studie 2012 HLS/BfS Berichte SB 14-B1: Hamburg: Büro für Suchtprävention der Hamburgischen Landesstelle für Suchtfragen e. V.
BZgA (2015) Der Cannabiskonsum Jugendlicher und junger Erwachsener in Deutschland 2014. Ergebnisse einer aktuellen Repräsentationsbefragung und Trends. Köln: Bundeszentrale für gesundheitliche Aufklärung
Cao D, Srisuma S, Bronstein A, Hoyte C (2016) Characterization of edible marijuana product exposures reported to United States poison centers. J Clinical Toxicology 54: 840–846
Dauber H, Specht S, Künzel J, Braun B (2016) Suchthilfe in Deutschland 2015. Jahresbericht der Deutschen Suchthilfestatistik. IFT München
EMCDDA (2009) European Monitoring Center for Drugs and Drug Addiction. Polydrug use: patterns and responses. Publications Office of the European Union, Luxembourg
EMCDDA (2013) European Monitoring Center for Drugs and Drug Addiction. Characteristics of frequent and high-risk cannabis users. Perspectives on drugs (available at emcddaeuropaeu/topics/pods/frequent-cannabis-users)
EMCDDA (2015) European Monitoring Center for Drugs and Drug Addiction. Treatment of cannabis-related disorders in Europe. Insight Publication 17. Publications Office of the European Union, Luxembourg
EMCDDA (2016) European Monitoring Center for Drugs and Drug Addiction. Europäischer Drogenbericht 2016: Trends und Entwicklungen. Amt für Veröffentlichungen der Europäischen Union, Luxemburg
EMCDDA (2017a) European Monitoring Center for Drugs and Drug Addiction. Europäischer Drogenbericht 2017: Trends und Entwicklungen. Amt für Veröffentlichungen der Europäischen Union, Luxemburg
EMCDDA (2017b) European Monitoring Center for Drugs and Drug Addiction. News release council decision. http://emcdda.europa.eu/news/2017/3/council-decision-control-mdmb-chmica.
ESPAD (2016) ESPAD Report 2015. Results from the European School Survey Project on Alcohol and Other Drugs. Publications Office of the European Union, Luxembourg
Fergusson D, Boden J, Horwood L (2008) The develpmental antecedents of illicit drug use: evidence from a 25-year longitudinal study. Drug Alcohol Depend 96 (1): 165–177
Gomes de Matos E, Atzendorf J, Kraus L, Piontek D (2016) Substanzkonsum in der Allgemeinbevölkerung in Deutschland. Ergebnisse des Epidemiologischen Suchtsurveys 2015. Sucht 62 (5): 271–281
Hall W (2014) What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 110: 19–35
Hall W, Pacula R (2003) Cannabis use and dependence: public health and public policy. Cambridge University Press
Höhne B, Pabst A, Hannemann T, Kraus L (2014) Patterns of concurrent alcohol, tobacco, and cannabis use in Germany: Prevalence and correlates. Drugs: Education, Prevention & Policy 21 (2): 102–109
Kraus L, Piontek D, Atzendorf J, Gomes de Matos E (2016a) Zeitliche Entwicklungen im Substanzkonsum in der deutschen Allgemeinbevölkerung. Ein Rückblick auf zwei Dekaden. Sucht 62: 283–294
Kraus L, Piontek D, Seitz N, Schoeppe M (2016b) Europäische Schülerstudie zu Alkohol und anderen Drogen 2015 (ESPAD): Befragungen der Schülerinnen und Schüler der 9. und 10. Klasse in Bayern. IFT-Berichte Bd. 188. IFT Institut für Therapieforschung, München
Lynskey M, Heath A, Bucholz K, Slutske W, Madden P, Nelson E, NG M (2003) Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA Psychiatry 289 (4): 427–433
Lynskey M, Vink J, Boomsma D (2006) Early onset cannabis use and progression to other drug use in a sample of Dutch twins. Behav Genet 36 (2): 195
Morral A, McCaffre D, Paddock S (2002) Reassessing the marijuana gateway effect. Addiction 97 (12): 1493–1504
Thanki D, Matias J, Griffiths P, Noor A, Olszewski D, Simon R, Vicente J (2012) Prevalence of daily cannabis use in the European Union and Norway. European Monitoring Center for Drugs and Drug Addiction Thematic Papers, Luxembourg,
UNODC (2017) United Nations Office on Drugs and Crime: Market analysis of plant-based drugs: Opiates, cocaine, cannabis. United Nations publication, Vienna
Wagner F, Anthony J (2002) Into the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am J Epidemiology 155 (10): 918–925
Werse B, Kamphausen G, Egger D, Sarvari L, Müller D (2015) MoSyD Jahresbericht 2014. Drogentrends in Frankfurt am Main. Centre for Drug Research, Frankfurt a. M.
Arzneimitteltelegramm (2017). Nabilon (Canemes) 48: 42–43
BFARM Bundesinstitut für Arzneimittel und Medizinprodukte. Zulassungsverfahren. http://www.bfarm.de/DE/Arzneimittel/zul/zulassungsverfahren/_node.html
Grotenhermen F, Häßermann K (2007) Cannabis. Verordnungshilfe für für Ärzte. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Kassenärztliche Vereinigung Westfalen-Lippe (KV) (2017) Cannabis als Kassenleistung. Information über die praktische Umsetzung. https://www.kvwl.de/arzt/verordnung/arzneimittel/info/invo/cannabis.pdf
Lander N, Ben-Zvi Z, Mechoulam R, Martin B, Nordqvist M, Agurell S (1976) Total synthesis of cannabidiol and delta1-tetrahydrocannabinol metabolites. J Chem Soc Perkin 1: 8–16
Mechoulam R, Gaoni Y (1965) A total synthesis of DL-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 20: 3273–3275
MFG (2017) Ministerium für Gesundheit: Gesetz „Cannabis als Medizin in Kraft getreten” 10.03.2017. https://www.bundesgesundheitsministerium.de/ministerium/meldungen/2017/maerz/cannabis-als-medizin-inkrafttreten.html
Müller-Wahl K, Grotenhermen F (2017) Medizinisches Cannabis: Die wichtigsten Änderungen. Dtsch Ärztebl 114: A352–356
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Schneider, M. et al. (2019). Cannabis, Cannabinoide und das Endocannabinoidsystem. In: Hoch, E., Friemel, C.M., Schneider, M. (eds) Cannabis: Potenzial und Risiko. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57291-7_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-57291-7_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57290-0
Online ISBN: 978-3-662-57291-7
eBook Packages: Medicine (German Language)